Jun. 16 at 2:11 PM
$IBRX this drug is showing real efficacy in tbe fight against NSCL cancer. Made by
$PFE
Lorlatinib is a third-generation ALK (anaplastic lymphoma kinase) inhibitor used to treat non-small cell lung cancer (NSCLC) in patients whose tumors have an ALK gene mutation or rearrangement. It works by blocking the ALK protein that drives cancer cell growth, and is notable for its ability to cross the blood-brain barrier, making it effective against brain metastase
https://x.com/cremieuxrecueil/status/2060955532559581294?s=46&t=jKXapJZhCmbNduU3W_BgJQ